- Global Pharma News & Resources

Global Immune Checkpoint Inhibitors Market Analysis & Forecast Through 2019-2023 -

The "Global Immune Checkpoint Inhibitors Market 2019-2023" report has been added to's offering.

The immune checkpoint inhibitors market will register a CAGR of almost 3% by 2023.

The growing number of cancer cases being diagnosed across the globe. Various international and national level campaigns are conducted to increase the awareness about cancer and to help early detection of the disease.

High target affinity and specificity of immune checkpoint inhibitors drugs

Most of the approved therapies for cancer treatment have severe side effects, which lowers the patient compliance towards the treatment. Thus, these drawbacks help the immune checkpoint inhibitors market grow.

High costs associated with the treatment

Treatment cost is one of the major challenges for cancer patients. The high cost is mainly due to hospitalization, laboratory costs, and novel immunotherapies.

Competitive Landscape

With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Pfizer

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Market Landscape

4. Market Sizing

5. Five Forces Analysis

6. Market Segmentation by Type

7. Customer Landscape

8. Geographic Landscape

9. Decision Framework

10. Drivers and Challenges

11. Market Trends

12. Vendor Landscape

13. Vendor Analysis

For more information about this report visit

View source version on

Editor Details

Last Updated: 11-Dec-2018